TargetMol

KRN 5500

Product Code:
 
TAR-T27745
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T27745-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
KRN 5500, a derivative of the nucleoside antibiotic spicamycin, has a wide range of antitumor activity against human cancer cell lines.
CAS:
151276-95-8
Formula:
C28H43N7O7
Molecular Weight:
589.694
Purity:
0.98
SMILES:
CCCCCCCCCC=CC=CC(=O)NCC(=O)N[C@@H]1[C@@H](O)[C@@H](O)[C@@H](Nc2ncnc3nc[nH]c23)O[C@H]1[C@@H](O)CO

References

1. Kawai H. [Protein synthesis inhibitor--antitumor activity and mode of action of KRN 5500]. Gan To Kagaku Ryoho. 1997 Sep;24(11):1571-7. Review. Japanese. PubMed PMID: 9309156. 2. Weinstein SM, Abernethy AP, Spruill SE, Pike IM, True Kelly A, Jett LG. A spicamycin derivative (KRN5500) provides neuropathic pain relief in patients with advanced cancer: a placebo-controlled, proof-of-concept trial. J Pain Symptom Manage. 2012 Apr;43(4):679-93. doi: 10.1016/j.jpainsymman.2011.05.003. PubMed PMID: 21983265. 3. Bay?s M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2004 Apr;26(3):211-44. PubMed PMID: 15148527. 4. Bay?s M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003 Dec;25(10):831-55. PubMed PMID: 14735233.